dr. flinn on fda approval of tisagenlecleucel in dlbcl
Published 6 years ago • 2.2K plays • Length 0:39Download video MP4
Download video MP3
Similar videos
-
1:17
fda approval of tisagenlecleucel in dlbcl
-
0:57
dr. flinn on fda approval of frontline brentuximab vedotin with avd in hodgkin lymphoma
-
1:06
dr. flinn on the fda approval of duvelisib in cll and follicular lymphoma
-
1:16
dr. flinn on the utility of tafasitamab in relapsed/refractory dlbcl
-
1:43
dr. maziarz discusses promise of tisagenlecleucel in dlbcl
-
1:16
dr. leonard on the fda approval of tazemetostat in follicular lymphoma
-
3:51
long-term outcomes on tisagenlecleucel: 4 years in dlbcl and fl
-
1:09
dr. flinn on opportunities for second-line tafasitamab in dlbcl
-
1:59
dr. borchmann on next steps with tisagenlecleucel in dlbcl
-
5:08
tisagenlecleucel for relapsed/refractory all
-
2:19
dr. wang on the fda approval of brexucabtagene autoleucel in mcl
-
1:16
dr. lacasce discusses the fda approval of lenalidomide/rituximab in non-hodgkin lymphoma
-
3:08
response data from the juliet trial in dlbcl
-
1:24
dr. flinn on car t-cell therapy in non-hodgkin lymphoma
-
1:53
dr. shah on the use of tisagenlecleucel in pediatric all
-
1:36
dr. deol on the approval of brexucabtagene autoleucel in mcl
-
2:07
dr. hou on polatuzumab vedotin in dlbcl
-
1:15
dr. abdulhaq on the safety profile of tafasitamab in dlbcl
-
3:00
regulation of pd-l1 in cutaneous lymphoma by mirnas